News Conference News AHA 2025 Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia Michael O'Riordan November 14, 2025
News Conference News AHA 2025 Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids Michael O'Riordan November 10, 2025
News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News SCCT 2025 AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry Yael L. Maxwell July 21, 2025
News Conference News EACTS 2024 Will Semaglutide Change Cardiac Surgery? It Already Has Yael L. Maxwell October 10, 2024
News Conference News ESC 2024 New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower Yael L. Maxwell September 04, 2024
News Conference News ACC 2024 TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP L.A. McKeown April 16, 2024
News Conference News ACC 2024 Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing Michael O'Riordan April 12, 2024
News Conference News AHA 2023 POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy L.A. McKeown November 13, 2023
News Conference News ESC 2023 ESC Focused Update on HF Synthesizes New Trial Data for Practical Use L.A. McKeown September 01, 2023
News Conference News SCCT 2023 Population Screening for Coronary Plaque: Is the Evidence Enough? Todd Neale July 31, 2023
News Conference News SCAI 2023 Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI L.A. McKeown May 24, 2023
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News TCT 2022 Dedicated Catheter for Acute PE Shows Promise in IDE Trial L.A. McKeown September 17, 2022
News Conference News AHA 2021 Avoiding AF Triggers Doesn’t Improve Quality of Life: I-STOP-AFib Michael O'Riordan November 14, 2021
News Conference News ESC 2021 Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention Michael O'Riordan August 31, 2021
News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021
News Conference News AHA 2020 Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT Todd Neale November 15, 2020
News Conference News ACC 2020 Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events Michael O'Riordan April 02, 2020
News Conference News AHA 2019 Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE Yael L. Maxwell November 21, 2019